SIRAKOSS was formed in 2011 with the mission of transforming patient outcomes by providing surgeons with evidence based nanosynthetic bone regeneration solutions. Investor and grant financing have enabled the translation of the core Osteo3 technology through to a CE marked product in 2018 and the development of further generation products to address the intraoperative needs of surgeons. SIRAKOSS is committed to generating compelling clinical data to demonstrate the efficacy of the Osteo3 technology. Our mission is to become the leader in bone repair.
SIRAKOSS is supported by financing from Epidarex Capital and Scottish Investment Bank, the investment arm of Scottish Enterprise together with grant funding from Innovate UK.